University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Austria.
University Clinic of Radiology, Medical University of Innsbruck, Austria.
Eur Heart J Acute Cardiovasc Care. 2019 Dec;8(8):717-726. doi: 10.1177/2048872618770600. Epub 2018 Apr 11.
Adverse left ventricular remodeling is one of the major determinants of heart failure and mortality in patients surviving ST-segment elevation myocardial infarction (STEMI). The hypothalamic-pituitary-thyroid axis is a key cardiovascular regulator; however, the relationship between hypothalamic-pituitary-thyroid status and post-STEMI left ventricular remodeling is unclear. We aimed to investigate the association between thyroid-stimulating hormone concentrations and the development of left ventricular remodeling following reperfused STEMI.
In this prospective observational study of 102 consecutive STEMI patients, thyroid-stimulating hormone levels were measured at the first day after infarction and 4 months thereafter. Cardiac magnetic resonance scans were performed within the first week as well as at 4 months follow-up to determine infarct characteristics, myocardial function and as primary endpoint left ventricular remodeling, defined as a 20% or greater increase in left ventricular end-diastolic volume.
Patients with left ventricular remodeling (=15, 15%) showed significantly lower concentrations of baseline (1.20 [0.92-1.91] vs. 1.73 [1.30-2.60] mU/l; =0.02) and follow-up (1.11 [0.86-1.28] vs. 1.51 [1.15-2.02] mU/l; =0.002) thyroid-stimulating hormone. The association between baseline thyroid-stimulating hormone and left ventricular remodeling remained significant after adjustment for major clinical (peak high-sensitivity cardiac troponin T and C-reactive protein, heart rate; odds ratio (OR) 5.33, 95% confidence interval (CI) 1.52-18.63; =0.01) and cardiac magnetic resonance predictors of left ventricular remodeling (infarct size, microvascular obstruction, ejection fraction; OR 4.59, 95% CI 1.36-15.55; =0.01). Furthermore, chronic thyroid-stimulating hormone was related to left ventricular remodeling independently of chronic left ventricular remodeling correlates (infarct size, ejection fraction, left ventricular end-diastolic volume, left ventricular end-systolic volume; OR 9.22, 95% CI 1.69-50.22; =0.01).
Baseline and chronic thyroid-stimulating hormone concentrations following STEMI were independently associated with left ventricular remodeling, proposing a novel pathophysiological axis in the development of post-STEMI left ventricular remodeling.
左心室重构是 ST 段抬高型心肌梗死(STEMI)患者心力衰竭和死亡的主要决定因素之一。下丘脑-垂体-甲状腺轴是心血管调节的关键;然而,下丘脑-垂体-甲状腺状态与 STEMI 后左心室重构之间的关系尚不清楚。我们旨在研究甲状腺刺激激素浓度与再灌注后 STEMI 左心室重构发展之间的关系。
在这项对 102 例连续 STEMI 患者的前瞻性观察研究中,在梗死后第一天和之后 4 个月测量甲状腺刺激激素水平。在第一周内和 4 个月的随访期间进行心脏磁共振扫描,以确定梗死特征、心肌功能和主要终点左心室重构,定义为左心室舒张末期容积增加 20%或以上。
左心室重构组(=15,15%)的基线(1.20 [0.92-1.91] vs. 1.73 [1.30-2.60] mU/l;=0.02)和随访(1.11 [0.86-1.28] vs. 1.51 [1.15-2.02] mU/l;=0.002)甲状腺刺激激素浓度显著降低。调整主要临床(高峰高敏肌钙蛋白 T 和 C 反应蛋白、心率)和心脏磁共振左心室重构预测因子后,基线甲状腺刺激激素与左心室重构之间的关联仍然显著(优势比(OR)5.33,95%置信区间(CI)1.52-18.63;=0.01)(梗死面积、微血管阻塞、射血分数;OR 4.59,95% CI 1.36-15.55;=0.01)。此外,慢性甲状腺刺激激素与左心室重构相关,而与慢性左心室重构相关因素(梗死面积、射血分数、左心室舒张末期容积、左心室收缩末期容积)无关;OR 9.22,95% CI 1.69-50.22;=0.01)。
STEMI 后基线和慢性甲状腺刺激激素浓度与左心室重构独立相关,提出了 STEMI 后左心室重构发展中的一种新的病理生理轴。